Login to Your Account



CHMP Backs Biotie Therapies' Selincro in Alcohol Dependence

By Cormac Sheridan
Staff Writer

Wednesday, December 19, 2012
Breaking out the champagne may not have been the appropriate reaction, but Biotie Therapies Oyj had reason to celebrate Friday, as the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval for its alcohol dependence drug Selincro (nalmefene).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription